Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MicuRx Of China Chooses First Antibiotic For Development

This article was originally published in PharmAsia News

Executive Summary

China's MicuRx Pharmaceuticals says it plans to conduct its first development effort on its MRX-I molecule to fight bacteria, including staphylococcus aureas, that are resistant to several drugs. The firm is readying the drug for preclinical trials while it expands its Chinese operations to increase its capacity to develop the medicine and other drugs in its pipeline. MicuRx plans another generation of antimicrobial products the expanded facilities would be designed to handle. Shengyu Yuan, MicuRx CEO, said the company has discovered several multiple-drug leads, and said MRX-I was a promising compound it expects to be superior to many top-selling antibiotics. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel